ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 332,33
-0,31%
Dow Jones
42 413,68
-1,35%
DAX
19 909,14
-0,25%
Brent Oil
74,185
0,76%
Bitcoin
92 234,78
-1,37%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX

  6. Ampio Pharmaceuticals Inc (AMPE) Cours

Ampio Pharmaceuticals Inc

Ampio Pharmaceuticals Inc (AMPE)

Amper SA
Amper SA
Amper SA
Amper SA
Ampio Pharmaceuticals Inc (CE)
0,62
0,00
( 0,00% )
Mis à jour : 01:00:00
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
0,62
Prix Achat
-
Prix Vente
-
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Cap du marché
703,922k
Clôture Veille
0,62
Ouverture
-
Dernière Transaction
Dernière heure de transaction
-
Volume financier
-
VWAP
-
Volume moyen (3 m)
-
Actions en circulation
1 135 358
Rendement du Dividende
-
Ratio Cours sur Bénéfices
0,00
Bénéfice par action (BPA)
-7,6
Chiffre d'affairess
-
Bénéfice net
-8,63M

À propos de Ampio Pharmaceuticals Inc

Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and advancement of immunomodulatory therapies for the treatment of pain from osteoarthritis. Its lead product candidate, Ampion, is in clinical trials and is being developed for the treatment of severe Osteoar... Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and advancement of immunomodulatory therapies for the treatment of pain from osteoarthritis. Its lead product candidate, Ampion, is in clinical trials and is being developed for the treatment of severe Osteoarthritis of the Knee, an intravenous treatment for COVID-19 patients, and an inhaled treatment for COVID-19 induced respiratory distress. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.ampiopharma.com
Siège social
Wilmington, Delaware, USA
Fondé
-

AMPE Dernières nouvelles

Plus de nouvelles

Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation

Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation PR Newswire ENGLEWOOD, Colo., April 3, 2024 ENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc...

03 Avril 2024
PR Newswire (US)

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Announces Voluntary Delisting and SEC Deregistration PR Newswire ENGLEWOOD, Colo., March 25, 2024 ENGLEWOOD, Colo., March 25, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE...

25 Mars 2024
PR Newswire (US)

Form EFFECT - Notice of Effectiveness

05 Mars 2024
Edgar (US Regulatory)

Form 8-K - Current report

28 Février 2024
Edgar (US Regulatory)

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

28 Février 2024
Edgar (US Regulatory)

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

28 Février 2024
Edgar (US Regulatory)

Form POS AM - Post-Effective amendments for registration statement

28 Février 2024
Edgar (US Regulatory)

Form RW - Registration Withdrawal Request

28 Février 2024
Edgar (US Regulatory)

Form 8-K - Current report

15 Février 2024
Edgar (US Regulatory)

Ampio Provides Update on Results from Pre-IND Enabling Studies

Ampio Provides Update on Results from Pre-IND Enabling Studies PR Newswire ENGLEWOOD, Colo., Feb. 14, 2024 ENGLEWOOD, Colo., Feb. 14, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE...

14 Février 2024
PR Newswire (US)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

AMPE - Frequently Asked Questions (FAQ)

What is the current Ampio Pharmaceuticals share price?
The current share price of Ampio Pharmaceuticals is US$ 0,62
How many Ampio Pharmaceuticals shares are in issue?
Ampio Pharmaceuticals has 1 135 358 shares in issue
What is the market cap of Ampio Pharmaceuticals?
The market capitalisation of Ampio Pharmaceuticals is USD 703,92k
What is the 1 year trading range for Ampio Pharmaceuticals share price?
Ampio Pharmaceuticals has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the reporting currency for Ampio Pharmaceuticals?
Ampio Pharmaceuticals reports financial results in USD
What is the latest annual profit for Ampio Pharmaceuticals?
The latest annual profit of Ampio Pharmaceuticals is USD -8,63M
What is the registered address of Ampio Pharmaceuticals?
The registered address for Ampio Pharmaceuticals is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the Ampio Pharmaceuticals website address?
The website address for Ampio Pharmaceuticals is www.ampiopharma.com
Which industry sector does Ampio Pharmaceuticals operate in?
Ampio Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
AAPYKurv Yield Premium Strategy Apple AAPL ETF
US$ 27,5187
(0,00%)
310
AAPXT Rex 2X Long Apple Daily Target ETF
US$ 33,64
(0,00%)
1,45k
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026
US$ 26,455
(0,00%)
0
AAAUGoldman Sachs Physical Gold ETF Shares
US$ 25,855
(0,00%)
3,72k
AAAAlternative Access First Priority CLO Bond ETF
US$ 25,05
(0,00%)
28
AAPYKurv Yield Premium Strategy Apple AAPL ETF
US$ 27,5187
(0,00%)
310
AAPXT Rex 2X Long Apple Daily Target ETF
US$ 33,64
(0,00%)
1,45k
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026
US$ 26,455
(0,00%)
0
AAAUGoldman Sachs Physical Gold ETF Shares
US$ 25,855
(0,00%)
3,72k
AAAAlternative Access First Priority CLO Bond ETF
US$ 25,05
(0,00%)
28
CTMCastellum Inc
US$ 1,42
(0,00%)
20,22M
OPTTOcean Power Technologies Inc
US$ 0,4768
(0,00%)
8,61M
LODEComstock Inc
US$ 0,6922
(0,00%)
6,15M
UVIX2x Long VIX Futures ETF
US$ 3,19
(0,00%)
5,22M
TSLZT Rex 2X Inverse Tesla Daily Target ETF
US$ 2,19
(0,00%)
4,81M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

AMEX
AMPE
Ampio Pharmaceuticals
NASDAQ
NCNC
noco noco
EU
ML
Michelin
FX
JPYCAD
Yen vs CAD
AMEX
IYG
iShares US Financial Ser...
LSE
83HS
Canary B3
BOV
EMAE4
EMAE PN
USOTC
BVHMF
Vistry (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés